Evidence map›Paper›PMID 25136338›Full record

ArticleFrontiers in microbiology2014

A novel thermostable polymerase for RNA and DNA loop-mediated isothermal amplification (LAMP).

Yogesh Chander, Jim Koelbl, Jamie Puckett, Michael J Moser, Audrey J Klingele, Mark R Liles, Abel Carrias, David A Mead, Thomas W Schoenfeld

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Potential Applications of Thermophilic Bacteriophages in One Health.International journal of molecular sciences · 2023
    Review
  17. Rapid and reliable diagnosis ofFrontiers in bioengineering and biotechnology · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yogesh ChanderLucigen Corporation Middleton, WI, USA.
Jim KoelblLucigen Corporation Middleton, WI, USA.
Jamie PuckettLucigen Corporation Middleton, WI, USA.
Michael J MoserLucigen Corporation Middleton, WI, USA.
Audrey J KlingeleLucigen Corporation Middleton, WI, USA.
Mark R LilesDepartment of Biological Sciences, Auburn University Auburn, AL, USA.
Abel CarriasDepartment of Biological Sciences, Auburn University Auburn, AL, USA.
David A MeadLucigen Corporation Middleton, WI, USA.
Thomas W SchoenfeldLucigen Corporation Middleton, WI, USA.

Funding

Point of Care Detection of Respiratory VirusesR44AI081467 · NIAID · LUCIGEN CORPORATION · PI SCHOENFELD, THOMAS WILLIAM · 2012 to 2014
$2.7M
Rapid Field Appropriate Diagnostics for Select Biodefense and Emerging PathogensR21AI100182 · NIAID · LUCIGEN CORPORATION · PI CHANDER, YOGESH · 2012 to 2013
$441k
NIAID NIH HHS R21 AI100182NIAID NIH HHS R44 AI081467
6 · The paper itself

Abstract

Meeting the goal of providing point of care (POC) tests for molecular detection of pathogens in low resource settings places stringent demands on all aspects of the technology. OmniAmp DNA polymerase (Pol) is a thermostable viral enzyme that enables true POC use in clinics or in the field by overcoming important barriers to isothermal amplification. In this paper, we describe the multiple advantages of OmniAmp Pol as an isothermal amplification enzyme and provide examples of its use in loop-mediated isothermal amplification (LAMP) for pathogen detection. The inherent reverse transcriptase activity of OmniAmp Pol allows single enzyme detection of RNA targets in RT-LAMP. Common methods of nucleic acid amplification are highly susceptible to sample contaminants, necessitating elaborate nucleic acid purification protocols that are incompatible with POC or field use. OmniAmp Pol was found to be less inhibited by whole blood components typical in certain crude sample preparations. Moreover, the thermostability of the enzyme compared to alternative DNA polymerases (Bst) and reverse transcriptases allows pretreatment of complete reaction mixes immediately prior to amplification, which facilitates amplification of highly structured genome regions. Compared to Bst, OmniAmp Pol has a faster time to result, particularly with more dilute templates. Molecular diagnostics in field settings can be challenging due to the lack of refrigeration. The stability of OmniAmp Pol is compatible with a dry format that enables long term storage at ambient temperatures. A final requirement for field operability is compatibility with either commonly available instruments or, in other cases, a simple, inexpensive, portable detection mode requiring minimal training or power. Detection of amplification products is shown using lateral flow strips and analysis on a real-time PCR instrument. Results of this study show that OmniAmp Pol is ideally suited for low resource molecular detection of pathogens.

Indexed as

diagnosticsinfectious diseasespoint-of-careRNA/DNA polymeraseRT-LAMP

Identifiers

PMID25136338
PMCPMC4117986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.